

# CITATION REPORT

List of articles citing

**A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients**

**DOI: 10.1111/j.1365-2036.2006.02926.x**

**Alimentary Pharmacology and Therapeutics, 2006, 23, 1643-7**

**Source:** <https://exaly.com/paper-pdf/40425872/citation-report.pdf>

**Version:** 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
168	Mechanisms underlying nonalcoholic steatohepatitis. <b>2006</b> , 3, 479-488		8
167	Atorvastatin is safe and effective for dyslipidemic patients with NAFLD. <b>2006</b> , 3, 420-421		
166	Statins for non-alcoholic fatty liver disease: a new indication?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 698-9	6.1	20
165	Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. <b>2007</b> , 42, 139-47		17
164	Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz. <b>2007</b> , 46, 253-5		1
163	Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. <b>2007</b> , 46, 258-60		10
162	No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. <b>2007</b> , 46, 255-6		6
161	Current World Literature. <b>2007</b> , 23, 199-215		
160	Is phosphatemia the best tool to monitor renal tenofovir toxicity?. <b>2007</b> , 46, 256-8		15
159	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. <b>2007</b> , 191, 235-40		431
158	Nonalcoholic fatty liver disease as a complication of insulin resistance. <i>Medical Clinics of North America</i> , <b>2007</b> , 91, 1125-49, ix	7	117
157	Drug treatment and type 2 diabetes: the impact of liver disease. <b>2007</b> , 24, 318-323		0
156	Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. <b>2007</b> , 564, 37-46		28
155	Current treatments in nonalcoholic steatohepatitis. <b>2007</b> , 10, 425-34		5
154	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. <b>2007</b> , 1, 343-54		5
153	Hypertension and hepatic steatosis. <b>2008</b> , 10, 182-7		2
152	Statins in liver disease: a molehill, an iceberg, or neither?. <b>2008</b> , 48, 662-9		97

151	Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. <b>2008</b> , 25, 523-9		33
150	Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 2-12	6.1	114
149	Review article: diagnosis and treatment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 503-22	6.1	84
148	Safety of statin therapy in patients with preexisting liver disease. <b>2008</b> , 28, 522-9		32
147	Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 805-24, ix	4.6	26
146	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. <i>Metabolism: Clinical and Experimental</i> , <b>2008</b> , 57, 1711-8	12.7	156
145	Diagnosis and therapy of nonalcoholic steatohepatitis. <b>2008</b> , 134, 1682-98		277
144	Evolving trends in nonalcoholic fatty liver disease. <b>2008</b> , 19, 75-82		25
143	[Treatment of fatty liver disease]. <b>2008</b> , 31, 229-38		1
142	Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. <b>2008</b> , 60, 311-57		288
141	Advances in the management of hyperlipidemia-induced atherosclerosis. <b>2008</b> , 6, 369-83		16
140	Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem. <b>2008</b> , 20, 1002-5		2
139	Nonalcoholic Fatty Liver Disease. 77-97		1
138	Liver biochemistry abnormalities in a quaternary care lipid clinic database. <b>2008</b> , 7, 63-66		3
137	Treatment regimens for non-alcoholic fatty liver disease. <b>2009</b> , 8, S51-S59		36
136	Nonalcoholic Fatty Liver Disease in Pediatric Patients. <b>2009</b> , 5, 65-71		
135	The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. <b>2009</b> , 2, 157-63		107
134	Drug-induced liver injury associated with statins. <b>2009</b> , 29, 412-22		111

133	Nonviral Hepatitis. <b>2009</b> , 22, 388-404		5
132	Current status of therapy in nonalcoholic Fatty liver disease. <b>2009</b> , 2, 29-43		9
131	A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. <b>2009</b> , 379, 241-51		16
130	Non-alcoholic fatty liver disease from pathogenesis to management: an update. <b>2010</b> , 11, 430-45		128
129	Current treatment of non-alcoholic fatty liver disease. <b>2009</b> , 11, 188-95		58
128	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 249-66	4.6	48
127	Recurrent nonviral liver disease following liver transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2009</b> , 3, 257-68	4.2	2
126	A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. <b>2009</b> , 43, 990-4		204
125	The metabolic syndrome and nonalcoholic fatty liver disease in children. <b>2009</b> , 21, 529-35		65
124	Non-Alcoholic Fatty Liver Disease. 119-134		4
123	Nonalcoholic steatohepatitis: a review of the literature and updates in management. <b>2010</b> , 103, 547-50		10
122	Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. <b>2010</b> , 45, 750-7		119
121	Nonalcoholic fatty liver disease: a review and update. <b>2010</b> , 55, 560-78		245
120	Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. <b>2010</b> , 64, 968-83		32
119	The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. <b>2010</b> , 12, 365-83		170
118	Prevention and treatment of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 331-40	3	15
117	Pathogenesis of non-alcoholic fatty liver disease. <b>2010</b> , 103, 71-83		462
116	Treatment options for nonalcoholic fatty liver disease. <b>2010</b> , 3, 121-37		103

115	Advances in the treatment of nonalcoholic fatty liver disease. <b>2010</b> , 1, 101-15		11
114	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <b>2011</b> , 43, 167-71		30
113	3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. <b>2011</b> , 5, 450-9		25
112	Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 71-7	0.7	183
111	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <b>2011</b> , 27, 635-62		135
110	Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. <b>2011</b> , 55, 498-9; author reply 499-500		
109	Reply to: Non-invasive prediction of fibrosis in nonalcoholic fatty liver disease <b>2011</b> , 55, 499-500		
108	Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. <b>2011</b> , 41, 375-85		23
107	Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <b>2011</b> , 41, 1057-65		55
106	Abnormalities of Carbohydrate Metabolism and the Liver. <b>2011</b> , 795-803.e4		1
105	Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. <b>2011</b> , 342, 383-7		15
104	Current therapeutic strategies in non-alcoholic fatty liver disease. <b>2011</b> , 13, 692-702		84
103	Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. <b>2011</b> , 251, 32-40		49
102	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. <b>2011</b> , 56, 3439-49		69
101	Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. <i>Lipids in Health and Disease</i> , <b>2011</b> , 10, 23	4.4	54
100	Does adiponectin benefit steatotic liver transplantation?. <b>2011</b> , 17, 993-1004		9
99	Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. <b>2011</b> , 27, 54-62		45
98	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <b>2011</b> , 16, 121-36		15

97	Expert opinion on current therapies for nonalcoholic fatty liver disease. <b>2011</b> , 12, 1901-11		12
96	Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2011</b> , 9, 287-90		35
95	Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 78-80	0.7	29
94	Treatment of Recurrent Nonviral Disease. <b>2012</b> , 910-915		
93	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <b>2012</b> , 7, 471-481		15
92	Dyslipidemia in patients with nonalcoholic fatty liver disease. <b>2012</b> , 32, 22-9		135
91	Way back for fructose and liver metabolism: bench side to molecular insights. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 6552-9	5.6	37
90	The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <b>2012</b> , 142, 1592-609		1208
89	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. <b>2012</b> , 47, 1257-66		42
88	NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. <b>2012</b> , 220, 287-93		66
87	Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). <b>2012</b> , 6, 340-51		53
86	Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS). <b>2012</b> , 154, 362-5		5
85	Normalization of ejection fraction in subjects with systolic heart failure. Is it really normal? A myocardial deformation study. <b>2012</b> , 154, 365-7		7
84	Is rosuvastatin effective for non-alcoholic steatohepatitis with dyslipidemia?. <b>2012</b> , 42, 1055-7		
83	Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2012</b> , 2, 156-73	4.1	27
82	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\beta$ -lowering property. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 492-6	3.3	45
81	Features, diagnosis, and treatment of nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 837-58	6.9	182
80	Nonalcoholic fatty liver disease: from lipid profile to treatment. <b>2012</b> , 5, 313-21		7

79	The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 811-26	0.7	279
78	The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <b>2012</b> , 55, 2005-23		2285
77	Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. <b>2012</b> , 57, 1773-81		49
76	Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <b>2012</b> , 42, 1065-72		33
75	Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. <b>2013</b> , 15, 305		28
74	Pharmacologic therapy for nonalcoholic fatty liver disease in adults. <b>2013</b> , 33, 223-42		11
73	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. <b>2013</b> , 73, 1-14		123
72	Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <b>2013</b> , CD008623		57
71	Diet Quality. <b>2013</b> ,		1
70	Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 22933-66	6.3	72
69	Emerging drugs for non-alcoholic steatohepatitis. <b>2013</b> , 18, 279-90		12
68	A novel inhibitor of stearyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis. <i>Biological and Pharmaceutical Bulletin</i> , <b>2013</b> , 36, 259-67	2.3	21
67	Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2013</b> , 105, 409-20	0.9	20
66	STATIN SAFETY REVISITED DATA. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2013</b> , 9, 143-148	0.5	1
65	Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 12182-201	5.6	40
64	Modern approach to the clinical management of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 8341-50	5.6	52
63	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. <i>Advances in Pharmacoeconomics &amp; Drug Safety</i> , <b>2014</b> , 03,		1
62	Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. <i>Annals of Pharmacotherapy</i> , <b>2014</b> , 48, 137-41 <sup>2.9</sup>		9

61	Management of fatty liver disease with the metabolic syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 487-500	4.2	21
60	Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. <i>Archives of Medical Research</i> , <b>2014</b> , 45, 52-7	6.6	12
59	Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. <i>Lipids in Health and Disease</i> , <b>2014</b> , 13, 22	4.4	24
58	Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition. <i>Drug Safety</i> , <b>2014</b> , 37, 213-24	5.1	8
57	Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. <i>Drug Safety</i> , <b>2014</b> , 37, 481-500	5.1	4
56	Review of treatment options for nonalcoholic fatty liver disease. <i>Medical Clinics of North America</i> , <b>2014</b> , 98, 55-72	7	30
55	Lipid lowering in liver and chronic kidney disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 28, 339-52	6.5	7
54	Treating the patient with nonalcoholic fatty liver disease. <i>Nurse Practitioner</i> , <b>2015</b> , 40, 36-42; quiz 42-3	0.4	2
53	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 6820-34	5.6	91
52	Treatment of nonalcoholic steatohepatitis in adults: present and future. <i>Gastroenterology Research and Practice</i> , <b>2015</b> , 2015, 732870	2	19
51	Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2015</b> , 5, 51-68	4.1	78
50	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 3777-85	5.6	82
49	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 4-11	3.3	99
48	Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 22	3	50
47	Lipid Management. <b>2015</b> ,		1
46	Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. <i>Free Radical Research</i> , <b>2015</b> , 49, 1405-18	4	182
45	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1215-23	12.7	47
44	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. <b>2015</b> , 149-173		1



43	Statins and the liver. <i>Cardiology Clinics</i> , <b>2015</b> , 33, 257-65	2.5	7
42	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). <b>2015</b> , 292-305		1
41	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. <i>Gastroenterology Research and Practice</i> , <b>2016</b> , 2016, 7109270	2	42
40	Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 490	8.4	38
39	Hybrids of coumarinIndole: design, synthesis and biological evaluation in Triton WR-1339 and high-fat diet induced hyperlipidemic rat models. <i>MedChemComm</i> , <b>2016</b> , 7, 1858-1869	5	3
38	Evaluation of Statin Treatment for Nonalcoholic Fatty Liver Disease. <i>Journal of Pharmacy Technology</i> , <b>2016</b> , 32, 169-173	0.6	5
37	Statins and the Liver. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2016</b> , 45, 117-28	5.5	7
36	Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , <b>2016</b> , 20, 351-64	4.6	9
35	Obesity. <b>2016</b> ,		4
34	The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients. <i>Journal of the American College of Nutrition</i> , <b>2017</b> , 36, 287-294	3.5	6
33	Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. <i>Experimental and Therapeutic Medicine</i> , <b>2017</b> , 13, 2375-2381	2.1	24
32	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2950-2961	5.6	44
31	(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2017</b> , 44, 1180-1191	3	8
30	Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. <i>Digestive Disease Interventions</i> , <b>2017</b> , 01, 066-073		7
29	Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2018</b> , 1863, 177-190	5	9
28	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. <i>Diseases (Basel, Switzerland)</i> , <b>2018</b> , 6,	4.4	7
27	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 757-769	14.8	131
26	Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. <i>Advances in Pharmacological Sciences</i> , <b>2018</b> , 2018, 4673061	4.9	4

25	The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. <i>Scientific Reports</i> , <b>2018</b> , 8, 12004	4.9	13
24	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2769-2775.e4	6.9	19
23	Statins in Females. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , <b>2019</b> , 04, 099-106	0.1	
22	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. <i>Hepatic Medicine: Evidence and Research</i> , <b>2019</b> , 11, 159-178	3.4	17
21	Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. <i>Scientific World Journal, The</i> , <b>2020</b> , 2020, 4503253	2.2	0
20	Drug-Induced Liver Injury in GI Practice. <i>Hepatology Communications</i> , <b>2020</b> , 4, 631-645	6	20
19	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. <i>Translational Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 60	5.2	2
18	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	5
17	High-intensity interval training with probiotic supplementation decreases gene expression of NF- $\kappa$ B and CXCL2 in small intestine of rats with steatosis. <i>Sport Sciences for Health</i> , 1	1.3	
16	Non-Alcoholic Fatty Liver Disease. 245-277		7
15	Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. <b>2013</b> , 61-73		1
14	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 116-124	0.7	20
13	Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Asian Biomedicine</i> , <b>2018</b> , 12, 3-13	0.4	2
12	KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , <b>2013</b> , 19, 325-48	6.9	88
11	Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. <i>Physiological Research</i> , <b>2012</b> , 61, 185-93	2.1	9
10	Pathogenesis and management issues for non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 4539-50	5.6	187
9	Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 12082-101	5.6	122
8	Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 7008-13	5.6	48

7	Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. <i>Saudi Journal of Gastroenterology</i> , <b>2016</b> , 22, 91-105	3	19
6	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 470-8	3-4	111
5	Using Parenteral Fish Oil In Nash. <b>2009</b> , 81-95		
4	Clinical Aspects of Nonalcoholic Fatty Liver Disease. <i>Oxidative Stress and Disease</i> , <b>2014</b> , 3-24		
3	Non-alcoholic Fatty Liver Disease in Obesity. <b>2016</b> , 159-179		
2	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. <i>World Journal of Hepatology</i> , <b>2022</b> , 14, 119-139	3-4	4
1	Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7841	6.3	4